The retrieval of randomized clinical trials in liver disease from the medical literature

1985 ◽  
Vol 6 (4) ◽  
pp. 271-279 ◽  
Author(s):  
Thierry Poynard ◽  
Harold O. Conn
Keyword(s):  
Clinical Trials ◽  
Liver Disease ◽  
Randomized Clinical Trials ◽  
Medical Literature

scholarly journals Perspective strategies for non-alcoholic fatty liver disease therapy: from trial to practice

2020 ◽  
Vol 1 (10) ◽  
pp. 18-25
Author(s):  
I. G. Bakulin ◽  
L. N. Belousova ◽  
L. I. Nazarenko ◽  
A. G. Sushilova
Keyword(s):  
Clinical Trials ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Randomized Clinical Trials ◽  
Intestinal Microbiome ◽  
Good Effect ◽  
Growth Trend ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is the most common diseases all over the world, but there is no so much approved medicines treating liver fibrosis, which is a predictor of total and hepatic mortality in this group of patients. Innovation methods of treating the NAFLD/NASH include several ways: decrease fat accumulation in the liver; influence on oxidative stress; inflammation and apoptosis; impact on the intestinal microbiome and metabolic endotoxemia; antifibrotic drugs. A few drugs which have recommended to use in treating other diseases (for example GLP-1RA for diabetes), demonstrated the good effect of treating NAFLD in clinical trials. There is a big number of drugs from different pharmacological groups, which are on the second and third stage of international multicenter randomized clinical trials, reviewed in this article. Probably, versions of treating NAFLD, which will reduce the growth trend of NAFLD-associated diseases, will be proposed in the near future.

scholarly journals A CURRENT VIEW OF PFAPA-SYNDROME (MARSHALL SYNDROME) IN CHILDREN (clinical observation)

2021 ◽  
Vol 14 (4) ◽  
pp. 78-84
Author(s):  
ILDUS YA. LUTFULLIN ◽  
◽  
SVETLANA O. SALUGINA ◽  
MARIA A. DAMINOVA ◽  
ILNAZ M. GAZIZOV ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Diagnostic Criteria ◽  
Randomized Clinical Trials ◽  
Clinical Observation ◽  
Medical Literature ◽  
Periodic Fever ◽  
Recurrent Fever ◽  
Current View ◽  
Therapeutic Approaches ◽  
Pfapa Syndrome

Background. PFAPA syndrome is the most common cause of recurrent fever in children. Despite the long history of the disease, the etiology and pathogenesis of the disease have not been definitively established. Aim. Analysis of the scientific medical literature on PFAPA syndrome (Marshall syndrome) with the presentation of personal clinical observation. Material and methods. An analysis of the medical literature devoted to the problem has been performed. A clinical case of a child with Marshall syndrome is presented. Results and discussion. The nature of the disease is associated with cytokine dysfunction and dysregulation of the inflammasome, which allows it to be classified as an autoinflammatory syndrome. The diagnosis of the disease is based on clinical and history criteria, the specificity of which has been questioned in recent years; new diagnostic criteria are now proposed. Despite the absence of double­blind randomized clinical trials, there is a wealth of experience with therapeutic approaches to PFAPA syndrome, includingВЕСТНИК СОВРЕМЕННОЙ КЛИНИЧЕСКОЙ МЕДИЦИНЫ 2021 Том 14, вып. 479ИЗ ПРАКТИЧЕСКОГО ОПЫТАthe administration of glucocorticoids, colchicine, and tonsillectomy. Our clinical example illustrates the problem of late diagnosis of PFAPA syndrome, the effectiveness of using glucocorticoids to control attacks as first­line therapy, and the need for different therapeutic approaches and differential diagnosis in complicated cases of monogenic autoinflammatory diseases. Conclusion. PFAPA syndrome is the most prevalent hereditary periodic fever syndrome. The exact epidemiology of the disease has not been studied, but it is assumed that the number of diagnosed cases is significantly lower than the actual prevalence of the disease. Attempts to revise the diagnostic criteria of PFAPA syndrome are currently underway. Despite the lack of randomized double­blind clinical trials to date, therapeutic strategies continue to improve.

L-arginine effect on inflammatory mediators: A systematic review of randomized controlled clinical trials

2019 ◽  
pp. 1-9 ◽  
Author(s):  
Seyed Reza Mirhafez ◽  
Mitra Hariri
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Inflammatory Mediators ◽  
Randomized Clinical Trials ◽  
Randomized Controlled Clinical Trials ◽  
Patients With Cancer ◽  
Reactive Protein ◽  
Randomized Controlled ◽  
Human Adults ◽  
Factor Α

Abstract. L-arginine is an important factor in several physiological and biochemical processes. Recently, scientists studied L-arginine effect on inflammatory mediators such as C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). We conducted a systematic review on randomized controlled trials assessing L-arginine effect on inflammatory mediators. We searched data bases including Google scholar, ISI web of science, SCOPUS, and PubMed/Medline up to April 2019. Randomized clinical trials assessing the effect of L-arginine on inflammatory mediators in human adults were included. Our search retrieved eleven articles with 387 participants. Five articles were on patients with cancer and 6 articles were on adults without cancer. L-arginine was applied in enteral form in 5 articles and in oral form in 6 articles. Eight articles were on both genders, two articles were on women, and one article was on men. L-arginine could not reduce inflammatory mediators among patients with and without cancer except one article which indicated that taking L-arginine for 6 months decreased IL-6 among cardiopathic nondiabetic patients. Our results indicated that L-arginine might not be able to reduce selected inflammatory mediators, but for making a firm decision more studies are needed to be conducted with longer intervention duration, separately on male and female and with different doses of L-arginine.

Ongoing randomized clinical trials for the treatment of thrombosis in the antiphospholipid syndrome

2001 ◽  
Vol 21 (02) ◽  
pp. 77-81 ◽  
Author(s):  
G. Finazzi
Keyword(s):  
Clinical Trials ◽  
Large Scale ◽  
Low Dose ◽  
Randomized Clinical Trials ◽  
Oral Anticoagulants ◽  
Collaborative Study ◽  
Clinical Problem ◽  
Vascular Events ◽  
Dose Oral ◽  
Adverse Pregnancy

SummaryThrombotic events are a major clinical problem for patients with antiphospholipid antibodies (APA). However, current recommendations for their prevention and treatment are still based on retrospective studies. Data from large scale, prospective clinical trials are required to ultimately identify the optimal management of these patients. To date, at least four randomized studies are underway. The WAPS and PAPRE clinical trials are aimed to establish the correct duration and intensity of oral anticoagulation in APA patients with major arterial or venous thrombosis. The WARSS-APASS is a collaborative study to evaluate the efficacy and safety of aspirin or low-dose oral anticoagulants in preventing the recurrence of ischemic stroke. The recently announced UK Trial compares low-dose aspirin with or without low-intensity anticoagulation for the primary prevention of vascular events in APA-positive patients with SLE or adverse pregnancy history, but still thrombosis-free. It is hoped that the results of these trials will be available soon since clinicians urgently need more powerful data to treat their patients with the APA syndrome.

Sign in / Sign up

Export Citation Format

Share Document